Paper40280970
Repurposing anti-viral subunit and mRNA vaccines T cell immunity for intratumoral immunotherapy against solid tumors.
Sethi SK and 6 others. NPJ Vaccines, 2025. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Repurposing anti-viral subunit and mRNA vaccines T cell immunity for intratumoral immunotherapy against solid tumors. Papers, record 40280970. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40280970
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Repurposing anti-viral subunit and mRNA vaccines T cell immunity for intratumoral immunotherapy against solid tumors.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants9
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| NIH | Intramural Research Program | PubMed | PubMed | ||
| NIH | Intramural Research Program | PubMed | PubMed | ||
| NIH | Intramural Research Program | PubMed | PubMed | ||
| NIH | Intramural Research Program | PubMed | PubMed | ||
| NIH | Intramural Research Program | PubMed | PubMed | ||
| NIH | Intramural Research Program | PubMed | PubMed | ||
| NIH | Intramural Research Program | PubMed | PubMed | ||
| ZIABC009052 | NIH | NIH RePORTER | |||
| ZICBC010947 | NIH | NIH RePORTER |
References59
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35332327 | IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. | Nat Immunol | 2022 | https://conductscience.org/library/papers/35332327 | PubMed |
| 2 | 26659303 | Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells. | Cancer Immunol Res | 2016 | https://conductscience.org/library/papers/26659303 | PubMed |
| 3 | 32299851 | Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. | Science | 2020 | https://conductscience.org/library/papers/32299851 | PubMed |
| 4 | 33767151 | Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling. | Nat Commun | 2021 | https://conductscience.org/library/papers/33767151 | PubMed |
| 5 | 35288714 | Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. | Nat Immunol | 2022 | https://conductscience.org/library/papers/35288714 | PubMed |
| 6 | 12854090 | Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. | J Infect Dis | 2003 | https://conductscience.org/library/papers/12854090 | PubMed |
| 7 | 31243491 | Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV model. | Cancer Immunol Immunother | 2019 | https://conductscience.org/library/papers/31243491 | PubMed |
| 8 | 29567705 | Cancer immunotherapy using checkpoint blockade. | Science | 2018 | https://conductscience.org/library/papers/29567705 | PubMed |
| 9 | 23376950 | T-helper-1-cell cytokines drive cancer into senescence. | Nature | 2013 | https://conductscience.org/library/papers/23376950 | PubMed |
| 10 | 32958686 | Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration. | J Immunother Cancer | 2020 | https://conductscience.org/library/papers/32958686 | PubMed |
| 11 | 29769722 | Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. | Nature | 2018 | https://conductscience.org/library/papers/29769722 | PubMed |
| 12 | 32999027 | Identification and Characterization of CD4+ T Cell Epitopes after Shingrix Vaccination. | J Virol | 2020 | https://conductscience.org/library/papers/32999027 | PubMed |
| 13 | 16111635 | Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. | Immunity | 2005 | https://conductscience.org/library/papers/16111635 | PubMed |
| 14 | 37576844 | State-of-the-Science of human papillomavirus vaccination in women with human immunodeficiency Virus: Summary of a scientific workshop. | Prev Med Rep | 2023 | https://conductscience.org/library/papers/37576844 | PubMed |
| 15 | 18591413 | Differential recognition of double-stranded RNA by RIG-I-like receptors in antiviral immunity. | J Exp Med | 2008 | https://conductscience.org/library/papers/18591413 | PubMed |
| 16 | 35853671 | Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy. | J Immunother Cancer | 2022 | https://conductscience.org/library/papers/35853671 | PubMed |
| 17 | 29971321 | Combined Systemic and Intratumoral Administration of Human Papillomavirus Vaccine to Treat Multiple Cutaneous Basaloid Squamous Cell Carcinomas. | JAMA Dermatol | 2018 | https://conductscience.org/library/papers/29971321 | PubMed |
| 18 | 18797453 | Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. | Mol Ther | 2008 | https://conductscience.org/library/papers/18797453 | PubMed |
| 19 | 29801750 | Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. | Semin Immunol | 2018 | https://conductscience.org/library/papers/29801750 | PubMed |
| 20 | 31360870 | Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58. | JNCI Cancer Spectr | 2018 | https://conductscience.org/library/papers/31360870 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42372086 | Repurposing licensed viral vaccines as anti-cancer therapeutics: Turning cold tumors hot. | Hum Vaccin Immunother | 2026 | https://conductscience.org/library/papers/42372086 | PubMed |
| 42236116 | Repurposing COVID-19 (and other) mRNA vaccines to boost cancer immunotherapy efficacy: mechanistic insights and future directions. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/42236116 | PubMed |
| 41058701 | The tumor immune microenvironment: implications for cancer immunotherapy, treatment strategies, and monitoring approaches. | Front Immunol | 2025 | https://conductscience.org/library/papers/41058701 | PubMed |
| 40872966 | Decrypting the Immune Symphony for RNA Vaccines. | Vaccines (Basel) | 2025 | https://conductscience.org/library/papers/40872966 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| CXCL9 | 4283 | PubTator's text mining | https://conductscience.org/library/genes/4283 | NCBI Gene |
| IFNG | 3458 | PubTator's text mining | https://conductscience.org/library/genes/3458 | NCBI Gene |
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40280970
GET https://conductscience.org/api/papers/v1/40280970/references?page=2